Equities analysts expect that Aralez Pharmaceuticals (NASDAQ:ARLZ) will announce earnings per share (EPS) of ($0.25) for the current quarter, Zacks reports. Two analysts have issued estimates for Aralez Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.29) and the highest estimate coming in at ($0.21). Aralez Pharmaceuticals reported earnings per share of ($0.42) in the same quarter last year, which would suggest a positive year-over-year growth rate of 40.5%. The business is expected to issue its next earnings report on Tuesday, May 8th.
On average, analysts expect that Aralez Pharmaceuticals will report full year earnings of ($0.66) per share for the current fiscal year, with EPS estimates ranging from ($0.85) to ($0.32). For the next year, analysts forecast that the company will post earnings of ($0.38) per share, with EPS estimates ranging from ($0.66) to $0.13. Zacks’ EPS averages are an average based on a survey of analysts that cover Aralez Pharmaceuticals.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Tuesday, March 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03). The business had revenue of $28.02 million for the quarter, compared to the consensus estimate of $25.75 million. Aralez Pharmaceuticals had a negative net margin of 118.18% and a negative return on equity of 170.42%.
ARLZ has been the topic of several recent analyst reports. Chardan Capital reissued a “buy” rating on shares of Aralez Pharmaceuticals in a research note on Tuesday, March 20th. Bloom Burton downgraded Aralez Pharmaceuticals from a “buy” rating to an “accumulate” rating in a research note on Wednesday, March 14th. Finally, HC Wainwright initiated coverage on Aralez Pharmaceuticals in a research note on Monday, February 5th. They set a “buy” rating and a $6.00 target price on the stock.
ARLZ traded down $0.01 on Tuesday, hitting $1.47. 796,567 shares of the company’s stock traded hands, compared to its average volume of 630,402. The company has a market capitalization of $98.51, a PE ratio of -1.22 and a beta of 1.59. Aralez Pharmaceuticals has a one year low of $0.95 and a one year high of $2.98. The company has a current ratio of 0.78, a quick ratio of 0.68 and a debt-to-equity ratio of 18.05.
A hedge fund recently raised its stake in Aralez Pharmaceuticals stock. Wells Fargo & Company MN grew its position in Aralez Pharmaceuticals (NASDAQ:ARLZ) by 71.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 273,130 shares of the company’s stock after acquiring an additional 113,720 shares during the quarter. Wells Fargo & Company MN owned 0.41% of Aralez Pharmaceuticals worth $625,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 17.83% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “-$0.25 Earnings Per Share Expected for Aralez Pharmaceuticals (ARLZ) This Quarter” was originally published by Zolmax and is the property of of Zolmax. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://zolmax.com/investing/0-25-earnings-per-share-expected-for-aralez-pharmaceuticals-arlz-this-quarter/2112445.html.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.